Wedbush Raises Earnings Estimates for Voyager Therapeutics

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at Wedbush lifted their Q2 2025 EPS estimates for Voyager Therapeutics in a note issued to investors on Tuesday, May 6th. Wedbush analyst Y. Zhong now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their previous estimate of ($0.37). Wedbush has a "Outperform" rating on the stock. The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Wedbush also issued estimates for Voyager Therapeutics' Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.41) EPS, FY2025 earnings at ($1.62) EPS, FY2026 earnings at ($1.12) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.76) EPS and FY2029 earnings at ($0.77) EPS.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%.

VYGR has been the topic of several other research reports. Cantor Fitzgerald reissued an "overweight" rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Canaccord Genuity Group lowered their price target on shares of Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating for the company in a report on Thursday, March 13th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Finally, Wells Fargo & Company set a $10.00 target price on shares of Voyager Therapeutics and gave the company an "overweight" rating in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics presently has an average rating of "Buy" and an average price target of $13.97.

Voyager Therapeutics Stock Down 2.7%

Voyager Therapeutics stock traded down $0.09 on Friday, hitting $3.19. The company's stock had a trading volume of 195,586 shares, compared to its average volume of 445,946. The firm has a market cap of $176.52 million, a P/E ratio of 4.49 and a beta of 0.95. The company has a fifty day moving average price of $3.49 and a 200-day moving average price of $4.88. Voyager Therapeutics has a one year low of $2.75 and a one year high of $9.55.

Insiders Place Their Bets

In other news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $3.43, for a total value of $37,335.55. Following the sale, the chief executive officer now directly owns 430,931 shares in the company, valued at $1,478,093.33. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 6.39% of the company's stock.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. Cubist Systematic Strategies LLC acquired a new position in shares of Voyager Therapeutics during the 4th quarter worth approximately $29,000. Tower Research Capital LLC TRC increased its holdings in Voyager Therapeutics by 133.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock worth $31,000 after buying an additional 3,077 shares during the last quarter. Picton Mahoney Asset Management increased its holdings in Voyager Therapeutics by 71.1% during the fourth quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company's stock worth $33,000 after buying an additional 2,444 shares during the last quarter. CWM LLC increased its holdings in Voyager Therapeutics by 856.3% during the first quarter. CWM LLC now owns 10,471 shares of the company's stock worth $35,000 after buying an additional 9,376 shares during the last quarter. Finally, Oxford Asset Management LLP acquired a new position in Voyager Therapeutics during the fourth quarter worth $60,000. 48.03% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.